Page 120 - 202007

Non-Small Cell Lung Cancer[S]. Washington：NCCN ， [40] HUGHES PE，CAENEPEEL S，WU LC. Targeted therapy
®
2019：NSCL-18. and checkpoint immunotherapy combinations for the treat-
[30] ROSELL R，CARCERENY E，GERVAIS R，et al. Erlo- ment of cancer[J]. Trends Immunol，2016，37（7）：462-
tinib versus standard chemotherapy as first line treatment 476.
for European patients with advanced EGFR mutation posi- [41] AKBAY EA，KOYAMA S，CARRETERO J，et al. Activa-
tive non-small cell lung cancer（EURTAC）：a multicenter， tion of the PD-1 pathway contributes to immune escape in
open label，randomized phase 3 trail[J]. Lancet Oncol， EGFR-driven lung tumors[J]. Cancer Discov，2013，3
2012.DOI：10.1016/S1470-2045（11）70393-X. （12）：1355-1363.
[31] WU YL，CHENG Y，ZHOU X，et al. Dacomitinib versus [42] WOLCHOK JD，KLUGER H，CALLAHAN MK，et al.
gefitinib as first-line treatment for patient with EGFR-mu- Nivolumab plus ipilimumab in advanced melanoma[J]. N
tation-positive non-small-cell lung cancer （ARCHER Engl J Med，2013，369（2）：122-133.
1050）：a randomized，open-label，phase 3 trial[J]. Lancet [43] LEE L，GUPTA M，SAHASRANAMAN S. Immune che-
Oncol，2017.DOI：10.1016/S1470-2045（17）30608-3. ckpoint inhibitors：an introduction to the next generation
[32] National Comprehensive Cancer Network （NCCN ）. cancer immunotherapy[J]. J Clin Pharmacol，2016，56
®
®
Soft Tissue Sarcoma[S]. Washington：NCCN ，2019： （2）：157-169.
®
SARC-F1. [44] GAINOR JF，SHAWA T，SEQUIST LV，et al. EGFR muta-
[33] RANEYR B，WALTERHOUSED O，MEZAJ L，et al. Re- tions and ALK rearrangements are associated with low re-
sults of the intergroup rhabdomyosarcoma study group sponse rates to PD-1 pathway blockade in non-small cell
D9602 protocol，using vincristine and dactinomycin with lung cancer：a retrospective analysis[J]. Clin Cancer Res，
or without cyclophosphamide and radiation therapy，for 2016，22（18）：4585-4593.
newly diagnosed patients with low-risk embryonal rhabdo- [45] HARATANI K，HAYASHI H，TANAKA T，et al. Tumor
myosarcoma：a report from the soft tissue sarcoma com- immune microenvironment and nivolumab efficacy in EG-
mittee of the children’s oncology group[J]. J Clin Oncol， FR mutation-positive non-small cell lung cancer based on
2011，29（10）：1312-1318. T790M status after disease progression during EGFR-TKI
[34] National Comprehensive Cancer Network （NCCN ）. treatment[J]. Ann Oncol，2017，28（7）：1532-1539.
®
®
Pancreatic Adenocarcinoma[S]. Washington：NCCN ， [46] RITTMEYER A，BARLESI F，WATERKAMP D，et al.
®
2019：PANC-F1-7. Atezolizumab versus docetaxel in patients with previously
[35] NIETO Y，THALLP F，VALDEZ BC，et al. Phase Ⅱ trial treated non-small-cell lung cancer（OAK）：a phase 3，
of high-dose gemcitabine/busulfan/melphalan with autolo- open-label，multicenter randomised controlled trial[J].
gous stem cell transplantation for primary refractory or Lancet，2017，389（10066）：255-265.
poor-risk relapsed Hodgkin lymphoma[J]. Biol Blood Mar- [47] 魏巍.我国首个ADC抗癌药物进入临床试验[N].医药经
row Transplant，2018，24（8）：1602-1609. 济报，2015-12-07（010）.
[36] CASALI PG，BIELACK S，ABECASSIS N，et al. Bone [48] TATEISHI K，WAKIMOTO H，LAFRATE AJ，et al. Ex-
+
sarcomas：ESMO-PaedCan-EURACAN clinical practice treme vulnerability of IDH1 mutant cancers to NAD de-
guidelines for diagnosis，treatment and follow-up[J]. Ann pletion[J]. Cancer Cell，2015，28（6）：773-784.
Oncol，2018，29（Suppl 4）：79-95. [49] 岳雅丽，尹骏，高向东，等.双特异性抗体药物在肿瘤治疗
[37] CARCELLER F，HIRSCH SG，KHABRA K，et al. High- 领域的研究进展[J].中国药科大学学报，2019，50（3）：
dose etoposide and cyclophosphamide in adults and chil- 289-298.
dren with primary refractory and multiply relapsed acute [50] DAN LU，LIU L，SUN Y，et al. The phosphatase PAC1
leukaemias：the royal marsden experience[J]. Leuk Res， acts as a T cell suppressor and attenuates host antitumor
2019.DOI：10.1016/j.leukres.2019.106217 immunity[J]. Nat Immunol，2020，21（3）：287-297.
[38] BLACK PC，AGARWAL PK，DINNEY CP. Targeted ther- [51] KIM ST，CRISTESCU R，BASS AJ，et al. Comprehensive
apies in bladder cancer：an update[J]. Urol Oncol，2007，25 molecular characterization of clinical responses to PD-1
（5）：433-438. inhibition in metastatic gastric cancer[J]. Nat Med，2018，
[39] ANSELL SM，LESOKHIN AM，BORRELLO L，et al. 24（9）：1449-1458.
PD-1 blockade with nivolumab in relapsed or refractory （收稿日期：2019-10-31 修回日期：2020-02-19）
Hodgkin’s lymphoma [J]. N Engl J Med，2015，372（4）： （编辑：唐晓莲）
311-319.

·878 · China Pharmacy 2020 Vol. 31 No. 7 中国药房 2020年第31卷第7期